UNSPSC 51334408: Fluspiperone

This classification denotes an antipsychotic agent with the molecular formula C23H25F2N3O2, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier V0Q53N427T, chemically known as r 28,930 but generally known as fluspiperone, which bears US NIH Compound Identifier 166535. European Medicines Agency schedules Fluspiperone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB07754MIG.

UNSPSC 51334408 Fluspiperone is a Commodity code that captures pharmaceutical products state and local governments procure for community health, emergency response, and multistate cooperative purchasing programs. Recent solicitations show state and local agencies buying naloxone and drug deactivation systems for public health initiatives, generic pharmaceuticals and over-the-counter products through cooperative agreements spanning multiple states, and exploring direct-to-manufacturer prescription fulfillment models to reduce costs and improve supply chain efficiency. The issuing bodies include county health departments, state health and human services commissions, and multistate cooperative purchasing alliances administering contracts for participating state and local jurisdictions. Procurement vehicles range from competitive sealed bids for specific, time-bound purchases to requests for information gathering vendor capabilities for future program design, to formal RFPs establishing blanket agreements with multiple award options based on therapeutic need and product availability.

Recent activity spans Florida, Texas, Minnesota, and Oregon. Seminole County, Florida released IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries, response due July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to solicit vendor responses on direct-to-manufacturer prescription capabilities and contracting models outside traditional pharmacy benefit manager arrangements. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration, issued RFP S1070000015802 on January 20, 2026, to establish multistate contracts for generic multi-source pharmaceuticals and OTC products through authorized wholesalers, with proposals due March 26, 2026, and awards effective July 1, 2026; vendors must hold $5,000,000 commercial general liability insurance and comply with current Good Manufacturing Practices and Drug Supply Chain Security Act requirements, with a 3 percent administrative fee on all purchases and performance penalties up to $1,500 per violation.